Myasthenia Gravis

A photo finish at a horse race with both horses crossing the finish line

J&J links FcRn blocker to sustained benefits as FDA ruling nears

The data reinforce a key plank of J&J's plan to build nipocalimab into a $5 billion medicine, showing benefits lasted through Week 60 of an extension.

Nick Paul Taylor Apr 8, 2025 10:21am

Immunovant posts phase 3 autoimmune win but won't seek approval

Mar 19, 2025 9:15am

J&J posts adolescent myasthenia gravis data on $6B FcRn blocker

Oct 15, 2024 9:25am

J&J files for FDA approval of $6.5B autoimmune drug

Aug 29, 2024 8:57am

Cartesian claims autoimmune CAR-T win after changing endpoint

Jul 2, 2024 7:56am

gift give present christmas package holidays

J&J posts pivotal data, prepares to crash argenx, UCB's party

Jul 1, 2024 6:00am